Compare GAU & IRWD Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | GAU | IRWD |
|---|---|---|
| Founded | 1999 | 1998 |
| Country | Canada | United States |
| Employees | N/A | N/A |
| Industry | | Biotechnology: Pharmaceutical Preparations |
| Sector | | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 606.0M | 658.5M |
| IPO Year | 2006 | 2009 |
| Metric | GAU | IRWD |
|---|---|---|
| Price | $1.86 | $3.76 |
| Analyst Decision | Buy | Buy |
| Analyst Count | 2 | 3 |
| Target Price | $4.08 | ★ $7.67 |
| AVG Volume (30 Days) | ★ 2.9M | 2.5M |
| Earning Date | 05-13-2026 | 05-11-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ 1400.00 |
| EPS | N/A | ★ 0.24 |
| Revenue | N/A | ★ $298,276,000.00 |
| Revenue This Year | $82.77 | $57.95 |
| Revenue Next Year | $29.09 | $4.39 |
| P/E Ratio | ★ N/A | $15.79 |
| Revenue Growth | N/A | ★ 8.88 |
| 52 Week Low | $1.26 | $0.72 |
| 52 Week High | $3.62 | $5.78 |
| Indicator | GAU | IRWD |
|---|---|---|
| Relative Strength Index (RSI) | 45.86 | 42.09 |
| Support Level | $1.71 | $3.08 |
| Resistance Level | $2.75 | $3.95 |
| Average True Range (ATR) | 0.08 | 0.19 |
| MACD | 0.02 | -0.07 |
| Stochastic Oscillator | 54.55 | 3.06 |
Galiano Gold Inc is focused on building a sustainable business capable of long term value creation for its stakeholders through a combination of exploration, accretive acquisitions, and disciplined deployment of its financial resources. The company currently operates and manages: Nkran, Esaase, Abore and Miradani North, multiple satellite deposits and exploration projects located on the Asankrangwa Gold Belt in the Amansie West District of the Republic of Ghana (Ghana), West Africa.
Ironwood Pharmaceuticals Inc is a biotechnology company developing and commercializing life-changing therapies for people living with gastrointestinal, or GI, and rare diseases. It is focused on the development and commercialization of inventive product opportunities in areas of unmet need, leveraging its demonstrated expertise and capabilities in GI and rare diseases. LINZESS is its commercial product. LINZESS is also available for the treatment of adults with IBS-C or CIC in Mexico, adults with IBS-C or chronic constipation in Japan, and adults with IBS-C in China. Linaclotide is available under the trademarked name CONSTELLA for the treatment of adults with IBS-C or CIC and pediatric patients ages 6-17 years old with FC in Canada, and to adults with IBS-C in certain European countries.